MedTrace Logo

Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)

NCT00709553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-09-28

No results posted yet for this study

Summary

The purpose of the study is to to assess the effect of multiple oral doses of ZD4054 (Zibotentan) on the pharmacokinetics of a CYP450 3A Probe (midazolam) in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

midazolam

DRUG

ZD4054

ZD4054 10 mg od

Sponsors & Collaborators

Principal Investigators

  • Thomas Morris · AstraZeneca, Medical Science Director

  • Dago Mazur · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709553 on ClinicalTrials.gov